RECURrence of Atrial Fibrillation after cardioversion of patients randomized to open-label treatment with dapagliflozin or usual care (RECUR-AF)

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: 114767e6769b3eca8e5a51ab518d9ccf0bdcbde2
First added on: Mar 21, 2025